C4 Therapeutics (CCCC) Revenue (2019 - 2026)

C4 Therapeutics has reported Revenue for 8 years, with the latest figure at $6.2 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue fell 15.0% year-over-year to $6.2 million; the trailing twelve-month figure through Mar 2026 stood at $34.9 million (down 12.37% YoY), and the FY2025 full-year result was $35.9 million, up 1.02% from the prior year.
• Revenue for Q1 2026 stood at $6.2 million, down from $11.0 million in the prior quarter.
• The five-year high for Revenue was $15.4 million in Q3 2024, with the low at $2.7 million in Q2 2023.
• Average Revenue over 5 years is $7.6 million, with a median of $6.8 million recorded in 2022.
• Year-over-year, Revenue slumped 85.79% in 2022 and soared 350.68% in 2024.
• Tracing CCCC's Revenue over 5 years: stood at $2.9 million in 2022, then gained by 14.26% to $3.3 million in 2023, then jumped by 58.75% to $5.2 million in 2024, then jumped by 112.79% to $11.0 million in 2025, then slumped by 44.15% to $6.2 million in 2026.
• The last three Revenue figures came in at $6.2 million (Q1 2026), $11.0 million (Q4 2025), and $11.2 million (Q3 2025), per Business Quant data.

Peer Comparison